The CRISPR/Cas9 system is widely recognized for its capabilities in genome editing, offering researchers a powerful tool to manipulate genetic material. This system, comprising the Cas9 endonuclease and a chimeric guide RNA (gRNA), enables precise modifications in cultured cells and living organisms, paving the way for various applications in preclinical research.
As an efficient gene delivery vehicle, adenoviral vectors enhance the application of CRISPR/Cas9 across different cell types, including both dividing and quiescent primary cells. Studies have demonstrated the effectiveness of adenoviral vectors for delivering CRISPR/Cas9 components, achieving substantial rates of targeted mutagenesis in various human cells.
At QVirus™, we combine the versatile CRISPR/Cas9 genome editing platform with our advanced adenovirus technology to provide a comprehensive adenovirus packaging service. This service significantly expands the potential applications of genome editing, enabling cutting-edge in vivo research.
Features
- User-friendly operation with straightforward handling procedures.
- High transfection efficiency across diverse cell types.
- Versatile for various mammalian species, opening up a wide range of applications.
- Shortened gene knockout cycles, reducing overall costs.
Applications
- Delivery of Cas9 for in vitro experiments.
- Targeted genome editing in somatic tissues of postnatal animals.
- Development of novel disease models for research.
- Advancement of gene therapies in small animal models.
QVirus™ effectively encapsulates Cas9 and gRNA into adenoviral vectors, addressing the challenges of low transfection efficiency typically associated with traditional plasmid-based CRISPR/Cas9 methods. If you have specific needs or special requirements, please reach out to our team for assistance.
